A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

NCT02107963 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

Sarcoma
Osteosarcoma
Neuroblastoma
Melanoma

Interventions

BIOLOGICAL: Anti-GD2-CAR engineered T cells
DRUG: AP1903
DRUG: Cyclophosphamide

Sponsor

National Cancer Institute (NCI)